Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTX NASDAQ:NKTR NASDAQ:WGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$221.38+0.0%$220.96$18.51▼$221.42$6.96B1.52928,762 shs2.69 million shsNKTRNektar Therapeutics$84.88+0.9%$76.85$7.99▼$109.00$2.86B1.241.11 million shs75,282 shsWGSGeneDx$34.46-0.2%$70.50$32.21▼$170.87$987.75M2.06875,102 shs989,239 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics0.00%0.00%0.00%0.00%+929.67%NKTRNektar Therapeutics-2.66%+0.42%+9.31%+123.59%+716.45%WGSGeneDx-47.22%-47.77%-47.87%-59.57%-47.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$221.38+0.0%$220.96$18.51▼$221.42$6.96B1.52928,762 shs2.69 million shsNKTRNektar Therapeutics$84.88+0.9%$76.85$7.99▼$109.00$2.86B1.241.11 million shs75,282 shsWGSGeneDx$34.46-0.2%$70.50$32.21▼$170.87$987.75M2.06875,102 shs989,239 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics0.00%0.00%0.00%0.00%+929.67%NKTRNektar Therapeutics-2.66%+0.42%+9.31%+123.59%+716.45%WGSGeneDx-47.22%-47.77%-47.87%-59.57%-47.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTXCidara Therapeutics 2.36Hold$169.88-23.27% DownsideNKTRNektar Therapeutics 2.73Moderate Buy$140.6365.68% UpsideWGSGeneDx 2.67Moderate Buy$96.43179.84% UpsideCurrent Analyst Ratings BreakdownLatest NKTR, CDTX, and WGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026WGSGeneDx Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.005/5/2026WGSGeneDx Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$100.00 ➝ $75.005/5/2026WGSGeneDx Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$155.00 ➝ $75.005/5/2026WGSGeneDx GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $70.005/5/2026WGSGeneDx BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$170.00 ➝ $90.004/24/2026WGSGeneDx Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/22/2026NKTRNektar Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026NKTRNektar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$123.00 ➝ $151.004/21/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$70.00 ➝ $95.004/20/2026WGSGeneDx Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$170.00 ➝ $100.004/20/2026NKTRNektar Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$151.00 ➝ $178.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTXCidara TherapeuticsN/AN/AN/AN/A$14.92 per shareN/ANKTRNektar Therapeutics$55.23M51.85N/AN/A$4.41 per share19.25WGSGeneDx$427.54M2.36$1.16 per share29.64$10.54 per share3.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTXCidara Therapeutics-$169.83M-$11.78N/AN/AN/AN/A-45.52%-38.31%N/ANKTRNektar Therapeutics-$164.08M-$10.20N/AN/AN/A-297.07%-380.32%-59.82%5/7/2026 (Estimated)WGSGeneDx-$21.02M-$0.75N/A20.27N/A-17.58%8.85%5.24%N/ALatest NKTR, CDTX, and WGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824N/AN/AN/A$10.69 millionN/A5/4/2026Q1 2026WGSGeneDx-$0.06-$0.28-$0.22-$2.16$112.46 million$102.25 million3/12/2026Q4 2025NKTRNektar Therapeutics-$2.69-$1.78+$0.91-$1.78$10.44 million$21.81 million2/23/2026Q4 2025WGSGeneDx$0.11$0.14+$0.03-$0.61$120.80 million$120.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDTXCidara TherapeuticsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/AWGSGeneDxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTXCidara TherapeuticsN/A4.624.62NKTRNektar TherapeuticsN/A4.974.97WGSGeneDx0.162.462.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTXCidara Therapeutics35.82%NKTRNektar Therapeutics75.88%WGSGeneDx61.72%Insider OwnershipCompanyInsider OwnershipCDTXCidara Therapeutics3.89%NKTRNektar Therapeutics2.50%WGSGeneDx29.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTXCidara Therapeutics9031.44 million30.22 millionNo DataNKTRNektar Therapeutics22033.74 million32.90 millionOptionableWGSGeneDx1,30029.29 million20.62 millionOptionableNKTR, CDTX, and WGS HeadlinesRecent News About These CompaniesGeneDx Holdings Corp. 2026 Q1 - Results - Earnings Call PresentationMay 6 at 3:31 AM | seekingalpha.comWGS: GeneDX Shares Plummet Over 45%; Investors Should Contact Block & Leviton to ...May 5 at 11:00 PM | bakersfield.comBThe 'alarming' results that caused GeneDx stock to plummet 50%May 5 at 11:00 PM | msn.comWGS: GeneDX Shares Plummet Over 45%; Investors Should Contact Block & Leviton to Potentially Recover Money Through The Firm's InvestigationMay 5 at 6:11 PM | globenewswire.comWGS stock slumps after hours as firm predicts lower test volume for yearMay 5 at 5:59 PM | msn.comSecurities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced - Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. CruzMay 5 at 5:59 PM | tmcnet.comDoes GeneDx’s Guidance Cut And Core Shift Reshape The Bull Case For GeneDx Holdings (WGS)?May 5 at 5:59 PM | finance.yahoo.comThe 'alarming' results that caused GeneDx stock to plummet 49%May 5 at 5:59 PM | msn.comSecurities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. CruzMay 5 at 3:33 PM | businesswire.comShareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against GeneDx Holdings Corp.May 5 at 2:58 PM | prnewswire.comGeneDx (NASDAQ:WGS) Reaches New 52-Week Low Following Weak EarningsMay 5 at 9:53 AM | marketbeat.comThe 'Alarming' Results That Caused GeneDx Stock To Plummet 45%May 5 at 9:35 AM | investors.comGuggenheim Cuts GeneDx (NASDAQ:WGS) Price Target to $70.00May 5 at 9:07 AM | marketbeat.comBTIG Research Cuts GeneDx (NASDAQ:WGS) Price Target to $90.00May 5 at 8:32 AM | marketbeat.comGeneDx Holdings Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 5 at 8:09 AM | globenewswire.comGeneDx Holdings Corp. (WGS) Q1 2026 Earnings Call TranscriptMay 4 at 10:01 PM | seekingalpha.comGeneDx Q1 Earnings Call HighlightsMay 4 at 8:07 PM | marketbeat.comGeneDx Holdings Corp. (WGS) Reports Q1 Loss, Lags Revenue EstimatesMay 4 at 6:56 PM | zacks.comGeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 EarningsMay 4 at 5:10 PM | quiverquant.comQGeneDx (NASDAQ:WGS) Issues Quarterly Earnings Results, Misses Estimates By $0.22 EPSMay 4 at 4:41 PM | marketbeat.comGeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year OutlookMay 4 at 4:05 PM | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNKTR, CDTX, and WGS Company DescriptionsCidara Therapeutics NASDAQ:CDTXCidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Nektar Therapeutics NASDAQ:NKTR$84.88 +0.72 (+0.85%) As of 10:24 AM Eastern This is a fair market value price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.GeneDx NASDAQ:WGS$34.46 -0.05 (-0.15%) As of 10:24 AM Eastern This is a fair market value price provided by Massive. Learn more.GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
